QUOTE AND NEWS
Market Intelligence Center  Sep 9  Comment 
After closing Monday at $69.19, BioMarin Pharmaceutical (BMRN) presents an attractive opportunity to get a 6.40% return in just 130 days, which is an annualized return of 17.97% (for comparison purposes only). To enter this trade, sell one Jan....
Market Intelligence Center  Sep 2  Comment 
A covered call identified by MarketIntelligececenter.com's patented algorithm on BioMarin Pharmaceutical (BMRN) could yield about 7.83% (20.85% annualized, for comparison purposes only) in 137 days. Pair a long position in the stock with the Jan....
Market Intelligence Center  Aug 12  Comment 
A covered call identified by MarketIntelligececenter.com's patented algorithm on BioMarin Pharmaceutical (BMRN) could yield about 3.57% (19.47% annualized, for comparison purposes only) in 67 days. Pair a long position in the stock with the Oct....
Benzinga  Aug 6  Comment 
In last week’s Benzinga article on InterMune (NASDAQ: ITMN), some of the warning signs for the overall stock market were highlighted. Those warnings became more than just warnings last week, as the market took some significant hits. Last...
Market Intelligence Center  Jul 31  Comment 
After closing Wednesday at $61.09, BioMarin Pharmaceutical (BMRN) presents an attractive opportunity to get a 4.91% return in just 51 days, which is an annualized return of 35.16% (for comparison purposes only). To enter this trade, sell one Sep....
SeekingAlpha  Jul 31  Comment 
BioMarin Pharmaceutical (NASDAQ:BMRN) Q2 2014 Earnings Call July 30, 2014 4:30 pm ET Executives Traci McCarty - Jean-Jacques Bienaimé - Chief Executive Officer and Director Daniel K. Spiegelman - Chief Financial Officer and...
Wall Street Journal  Jul 31  Comment 
Regeneron Pharmaceuticals and Sanofi are spending $67.5 million to buy a special voucher held by BioMarin Pharmaceuticals in a bid to hasten regulatory review of their new cholesterol drug.
newratings.com  Jul 30  Comment 
WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN) Wednesday said second-quarter loss widened to $33.5 million or $0.23 per share from $21.5 million or $0.16 per share in the same period last year. On average, 18 analysts polled by...
StreetInsider.com  Jul 30  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/BioMarin+%28BMRN%29+Tops+Q2+EPS+by+18c%2C+Sells+riority+Review+Voucher+for+%2467.5+Million/9704752.html for the full story.
Market Intelligence Center  Jul 15  Comment 
BioMarin Pharmaceutical (BMRN) presents a trading opportunity that offers a 5.79% return in just 95 days. A covered call on BioMarin Pharmaceutical at the $55.00 level expiring on Oct. '14 offers an assigned return rate of 5.79% or 22.24%...




 

BioMarin Pharmaceutical Inc. (BMRN), a developer of enzyme-related therapies (ERT), co-markets Aldurazyme with Genzyme Corporation (GENZ) for the treatment of MPS-I (mucopolysaccharidosis). MPS-I is a rare genetic enzyme deficiency disorder, afflicting roughly 3,000 people worldwide, caused by the lack of a specific enzyme involved in lysosomal storage. More common names for mucopolysaccharidosis are Hurler's Syndrome, Hurler-Scheie, and Scheie's Disease. The company's other developed product, Naglazyme, for MPS-VI, recently entered the market. MPS-VI is also a rare genetic enzyme deficiency disorder, with an estimated 1,100 people suffering from it worldwide. The company's third lead drug, Kuvan, received FDA approval for the treatment of PKU in December 2007. With the recent launch of Kuvan, the company now has three products on the market. The company also receives royalties and license revenue on sales of the Orapred franchise from Alliant Pharmaceuticals. In 2004, the company acquired Orapred, a grape-flavored oral corticosteroid liquid for the treatment of severe asthma in children and subsequently licensed the franchise to Alliant Pharmaceuticals in March 2006. BioMarin, headquartered in Novato, CA, employs roughly 300 people.

Business Overview

Business & Financial Metrics

In 2009, BMRN incurred a net loss of $488 thousand on revenues of $324.7 million. This represents a real turnaround from 2008, when the company earned $30.8 million on $296.5 million in revenues.[1]

Geographical Distribution[2]

BioMarin generates the majority of its revenues from sales in Europe.

IMAGE:BMRN-Geography2009.jpg[2]

Competition

BioMarin competes with companies like:

References

  1. BMRN 2009 10-K pg. 36  
  2. 2.0 2.1 BMRN 2009 10-K pg. 16  
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki